glutaminase

By Targets:	Glutaminase (18) Apoptosis (2) Autophagy (2) Reactive Oxygen Species (1)
By Research Areas:	Cancer (16) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (2)

Targets Recommended: Glutaminase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12682

Glutaminase C-IN-1 5 Publications Verification Compound 968	Glutaminase	Cancer
Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts .

HY-79583

Glutaminase-IN-3 1 Publications Verification	Glutaminase	Cancer
Glutaminase-IN-3 (compound 657) is a potent *glutaminase* inhibitor with an IC₅₀ of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657 .

HY-P2760

Glutaminase

GLS
Others Others

Glutaminase (GLS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

*Glutaminase* GLS	Others	Others
Glutaminase (GLS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-149602

Glutaminase C-IN-2	Glutaminase Reactive Oxygen Species	Cancer
Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC₅₀ of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .

HY-146658

Glutaminase-IN-4

Glutaminase Cancer

Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

Glutaminase-IN-4	Glutaminase	Cancer
Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

HY-114334

Glutaminase-IN-1 1 Publications Verification CB839 derivative	Glutaminase	Cancer
Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC₅₀ of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.

HY-N2916

Barbinervic acid	Glutaminase	Neurological Disease
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

HY-103671A

IPN60090 dihydrochloride	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-103671

IPN60090	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-W006187

2-Amino-2-(p-tolyl)acetic acid	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

HY-12248

Telaglenastat Maximum Cited Publications 57 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy** and has antitumor activity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy** and has antitumor activity .

HY-12683

BPTES

20+ Cited Publications

Glutaminase Cancer

BPTES is an allosteric and selective glutaminase inhibitor with an IC₅₀ of 0.16 μM.
HY-148241

A-446

Glutaminase Cancer

A-446 is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .

BPTES 20+ Cited Publications	Glutaminase	Cancer
BPTES is an allosteric and selective *glutaminase* inhibitor with an IC₅₀ of 0.16 μM.

A-446	Glutaminase	Cancer
A-446 is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .

HY-122218

JHU-083 4 Publications Verification	Glutaminase	Neurological Disease
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective *glutaminase* antagonist. JHU-083 blocks glutaminase activity in brain CD11b ⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-152207

LWG-301	Glutaminase Apoptosis	Cancer
LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC₅₀ value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model .

HY-151434

GLS1 Inhibitor-6	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC₅₀=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

HY-155138

GLS1 Inhibitor-7	Glutaminase	Metabolic Disease Cancer
GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC₅₀=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	903 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 903 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

903 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 903 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Target	Research Area

HY-W006187

2-Amino-2-(p-tolyl)acetic acid	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2916

Barbinervic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Rubiaceae Mitragyna inermis (Willd.) Kuntze Plants	Glutaminase
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

Cat. No.	Product Name	Application	Reactivity

HY-P80690

Glutaminase Antibody glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; glutaminase C; L-glutamine amidohydrolase	WB, ICC/IF, IP	Human, Mouse, Rat
Glutaminase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 73 kDa, targeting to Glutaminase. It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P81600

TAX1BP3 Antibody (YA1345)

glutaminase interacting protein 3; Tax interaction protein 1; Tax1 binding protein 3; Tax1bp3; TIP1
WB, IHC-P, FC Human, Mouse, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Antibodies